Key result
Higher baseline platelets linked to ~32% lower 28-day mortality in ARDS vs severe thrombocytopenia.
Why the study?
Patients with diabetes have high cardiovascular morbidity and mortality despite advances in therapy, with platelet and coagulation abnormalities contributing to risk and impaired response to antiplatelet therapy.
Cohort (n=3,207)
No
Hazard Ratio: 0.681 (95% CI 0.576–0.805)
Absolute Event Rate: 23.06% vs 40.13%
p-value: p=< 0.001
Patients with diabetes mellitus are at increased risk of cardiovascular events. Despite advances in medical and interventional therapy, cardiovascular morbidity and mortality remains high in patients with diabetes. Although accelerated atherosclerosis has long been recognized as an underlying cause, recent studies suggest that changes in platelets and coagulation also play important roles. Patients with diabetes exhibit a prothrombotic milieu with hyperreactive platelets and coagulation abnormalities. Thus, prevention of cardiovascular events in patients with coronary artery disease (CAD) and diabetes involves a multifactorial approach including treatment of risk factors such as dyslipidemia, obesity, hypertension, hyperglycemia, and hypercoagulation. An impaired response to antiplatelet therapy has been consistently reported and optimization of this therapy seems appropriate to reduce the risk of cardiovascular events in these patients. In this review, platelet abnormalities are summarized together with an update of benefits and limitations of antiplatelet therapy in patients with CAD and diabetes.
No takes yet. Share an insight, caveat, or question.
Neergaard‐Petersen et al. (2016) conducted a cohort in Acute Respiratory Distress Syndrome (ARDS) (n=3,207). Platelet count 101-200 × 10^9/L vs. Platelet count ≤ 100 × 10^9/L was evaluated on 28-day mortality (HR 0.681, 95% CI 0.576-0.805, p=< 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: